About Court Report: Each week we will report briefly on recently filed biotech and pharma cases.
Alza Corp. et al. v. Mylan Pharmaceuticals Inc. et al.
1:14-cv-00085; filed May 15, 2014 in the Northern District of West Virginia
• Plaintiffs: Alza Corp.; Janssen Pharmaceuticals, Inc.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
Alza Corp. et al. v. Mylan Pharmaceuticals Inc. et al.
1:14-cv-00594; filed May 12, 2014 in the District Court of Delaware
• Plaintiffs: Alza Corp.; Janssen Pharmaceuticals Inc.
• Defendants: Mylan Pharmaceuticals Inc.; Mylan Inc.
The complaints in these cases are substantially identical. Infringement of U.S. Patent No. 8,163,798 ("Methods and Devices for Providing Prolonged Drug Therapy," issued April 24, 2012) following a Paragraph IV certification as part of Mylan's filing of an ANDA to manufacture a generic version of Alza's Concerta® (methylphenidate hydrochloride, used to treat attention deficit hyperactivity disorder). View the Mylan complaint here.
Cephalon Inc. v. InnoPharma Inc.
1:14-cv-00590; filed May 9, 2014 in the District Court of Delaware
Infringement of U.S. Patent No. 8,609,863 ("Bendamustine Pharmaceutical Compositions," issued December 17, 2013) following a Paragraph IV certification as part of InnoPharma's filing of an ANDA to manufacture a generic version of Cephalon's Treanda® (bendamustine hydrochloride, used to treat chronic lymphocytic leukemia and non-Hodgkin's lymphoma). View the complaint here.
Otsuka Pharmaceutical Co. v. Alembic Pharmaceuticals Ltd. et al.
1:14-cv-02982; filed May 9, 2014 in the District Court of New Jersey
• Plaintiff: Otsuka Pharmaceutical Co.
• Defendants: Alembic Pharmaceuticals Ltd.; Alembic Ltd.; Alembic Global Holding SA; Alembic Pharmaceuticals Inc.
Infringement of U.S. Patent Nos. 8,017,615 ("Low Hygroscopic Aripiprazole Drug Substance and Process for the Preparation Thereof," issued September 13, 2011), 8,580,796 (same title, issued November 12, 2013), 8,642,760 (same title, issued February 4, 2014), and 8,518,421 ("Flashmelt Oral Dosage Formulation," issued August 27, 2013) following a Paragraph IV certification as part of Alembic's filing of an ANDA to manufacture a generic version of Otsuka's Abilify® (aripiprazole, used to treat bipolar disorder and schizophrenia). View the complaint here.
